Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII

Haemophilia

Volumn 12, Issue SUPPL. 4, 2006, Pages 61-69

  Poon, Man Chiu ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Factor IX; Factor XIII; Pharmacokinetics; Recombinant activated factor VII

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

AGE DISTRIBUTION; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BODY WEIGHT; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; ENDOTHELIUM; GLANZMANN DISEASE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IN VIVO STUDY; PLASMA VOLUME; PRIORITY JOURNAL; THROMBOCYTE;

EID: 33748760910     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01336.x     Document Type: Article

References (59)

1. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1(Suppl. 1): 8-13.
2. Roberts HR, Eberst ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993; 7: 1269-80.
3. Lee M, Morfini M, Schulman S, Ingerslev J, Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. http://www.med.unc.edu/ isth/ssc/communications/factor8and9/fviiipharmaco.pdf, 2001: 1-9. (report).
4. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
5. Bjorkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: Methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
6. Shapiro A, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
7. Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun 1983; 111: 723-31.
8. Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA 1983; 80: 4119-23.
9. Cheung WF, van den BJ, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-73.
10. Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997; 272: 16717-20.
11. Ahmad SS, Rawala-Sheikh R, Walsh PN. Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem 1989; 264: 3244-51.
12. Liebman HA, Rosenwald-Zuckerman T, Retzios A, Yasmin S, Kasper CK. Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement. Haemophilia 1999; 5: 174-80.
13. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
14. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
15. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
16. White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. Thromb Haemost 1995; 73: 779-84.
17. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
18. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
19. Aronstam A, McLellan DS, Wassef M, Mbatha PS. Effect of height and weight on the in vivo recovery of transfused factor VIII C. J Clin Pathol 1982; 35: 289-91.
20. Manno CS, Butler RB, Cohen AR. Low recovery in vivo of highly purified factor VIII in patients with hemophilia. J Pediatr 1992; 121(5 Pt 1): 814-8.
21. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
22. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
23. Morrissey JH, Mutch NJ. Tissue factor structure and function. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2006: 91-106.
24. Geczy CL. Cellular mechanisms for the activation of blood coagulation. Int Rev Cytol 1994; 152: 49-108.
25. Camerer E, Lolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
26. Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
27. Todoroki H, Nakamura S, Higure A et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209-16.
28. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
29. Peyvandi P, Spreafico M. Factor V and combined factor V and VIII deficiencies. In: Lee CA, Berntorp EE, Hoots K, eds. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing, Inc., 2005: 306-10.
30. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1: 112-9.
31. Allen GA, Hoffman M, Roberts HR, Monroe DM III. Recombinant activated factor VII: Its mechanism of action and role in the control of hemorrhage. Can J Anaesth 2002; 49: S7-14.
32. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408-13.
33. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
34. Shirahata A, Kamiya T, Takamatsu J et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol 2001; 73: 517-25.
35. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
36. Hedner U, Kristensen H, Berntorp E, Ljung R, Petrini P, Tengborn L. Pharmacokinetics of rFVIIa in children. Haemophilia 1998; 4: 244 (abstract).
37. Berrettini M, Mariani G, Schiavoni M et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001; 86: 640-5.
38. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
39. Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: Inherited and acquired deficiency. Blood Rev 1993; 7: 229-42.
40. Fear JD, Jackson P, Gray C, Miloszewski KJ, Losowsky MS. Localisation of factor XIII in human tissues using an immunoperoxidase technique. J Clin Pathol 1984; 37: 560-3.
41. Weisberg LJ, Shiu DT, Conkling PR, Shuman MA. Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain. Blood 1987; 70: 579-82.
42. Adany R, Antal M. Three different cell types can synthesize factor XIII subunit A in the human liver. Thromb Haemost 1996; 76: 74-9.
43. Schmeling A, Bockholdt B, Schroder H, Geserick G. Phenotype change in polymorphic plasma proteins following liver transplantation. Exp Clin Immunogenet 1996; 13: 78-83.
44. Weisberg LJ, Shiu DT, Greenberg CS, Kan YW, Shuman MA. Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J Clin Invest 1987; 79: 649-52.
45. Poon MC, Russell JA, Low S et al. Hemopoietic origin of factor XIII A subunits in platelets, monocytes, and plasma. Evidence from bone marrow transplantation studies. J Clin Invest 1989; 84: 787-92.
46. Brackmann HH, Egbring R, Ferster A et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: A crossover randomised study. Thromb Haemost 1995; 74: 622-5.
47. Reynolds TC, Butine MD, Visich JE et al. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers. J Thromb Haemost 2005; 3: 922-8.
48. Rodeghiero F, Tosetto A, Di Bona E, Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991; 36: 30-4.
49. Daly HM, Haddon ME. Clinical experience with a pasteurised human plasma concentrate in factor XIII deficiency. Thromb Haemost 1988; 59: 171-4.
50. Fear JD, Miloszewski KJ, Losowsky MS. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost 1983; 49: 102-5.
51. Kitchens CS, Newcomb TF. Factor XIII. Medicine (Baltimore) 1979; 58: 413-29.
52. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73.
53. Hedner U. Products used to treat hemophilia: Recombinant factor VIIa. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing Ltd, 2005: 147-52.
54. Mariani G, Dolce A. Congenital factor VII deficiency. In: Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Oxford, UK: Blackwell Publishing Ltd, 2005: 311-4.
55. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S35-8.
56. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-10 (abstract).
57. Kavakli K, Makris M, Zulfikar B, Abrams ZS, Kenet G, for the NovoSeven® trial (F7HAEM-1510) Investigators. Recombinant Activated Factor VII (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients with Inhibitors: A Double-blind Study of a Single High Dose vs. Standard Multiple Doses. XXth International Society of Thrombosis and Haemostasis Congress, Sydney, 2005 (abstract P2024).
58. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
59. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35(2 Suppl. 2): 33-8.